You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Novel commensal polysaccharide treats multiple sclerosis through Treg modulation

    SBC: SYMBIOTIX BIOTHERAPIES, INC.            Topic: NIAID

    Abstract Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease that is the most common neurological disease of young adults, affecting over 350,000 patients in the US and over 2.5 million patients worldwide. MS is a disease of high unmetmedical need, currently treatable with one of several approved drugs, all of which result in either immune modulation or significant immunosuppre ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. A P. falciparum MSP1 p42/QS-21 malaria vaccine

    SBC: Agenus Inc.            Topic: N/A

    DESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a disease which affects more than 300 million people each year and is fatal for 1.5 million. The overall objective of this STTR Phase I project is to produce a cGMP malaria vaccine consisting of the 42 kDa C-terminal polypeptide of P. falciparum merozoite surface protein-1 (MSP1.42) to be formulated with ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  6. SOD/Catalase mimics for age-related learning impairment

    SBC: Eukarion, Inc.            Topic: N/A

    DESCRIPTION Adapted from applicant's abstract): Aging is accompanied by a slow decline in cognitive function, now referred to as mild cognitive impairment (MCI), and by accumulation of oxidized proteins and lipids as a result of oxidative stress. Eukarion has discovered a new class of manganese complexes that display both superoxide dismutase (SOD) and catalase ac ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  7. DNP Polarization Agents for Real-Time Metabolic Imaging and Clinical Diagnosis

    SBC: DYNUPOL, INC.            Topic: NCI

    Project Summary / Abstract Although standard MRI techniques provide valuable structural insight, a related technique known as magnetic resonance spectroscopy (MRS) adds powerful real-time metabolic information about the tissues under study. MRS provides early detection of disease, monitoring treatment efficacy, and, in the case of cancer, a dramatic reduction in unnecessary biopsies. However, bro ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. AutoRegister: A system for enhancing the accuracy of tumor change detection

    SBC: CORTICOMETRICS LLC            Topic: NCI

    DESCRIPTION (provided by applicant): This project proposes to build an integrated software-based system for enhancing the accuracy of tumor change detection. The intent of the system, called AutoRegister, which is to be deployed on a clinical magnetic resonance imaging (MRI) scanner platform, is to automate the alignment of a patient's brain scan with that of a prior scan, such that subseque ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Stabilization of Therapeutic Peptides by Non-Perturbative Chemical Modification

    SBC: VERAQUEL TECHNOLOGIES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Type 2 diabetes is a particularly debilitating disease and is endemic for a large proportion of the world's population. The unmet challenges in disease management are the lack of long-term efficacy in reducing hyperglycemia and the inability to stop progression. Glucagon-like peptide-1 (GLP-1), a natural gut hormone, provides a platform for therapeutics to ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. High-Purity Peptide Libraries without Chromatographic Separation

    SBC: VERAQUEL TECHNOLOGIES, INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): The market for peptide and protein products is 30 billion annually and continues to grow. Automated solid phase peptide synthesis (SPPS) is a mainstay of modern medicinal research, and has been used on micromole up tometric ton industrial scale. Peptide drugs such as Exenatide, a GLP-1 analogue and a life-saver to many type-2 diabetes patients, and Fuzeon for ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government